Roche is looking to Phase III clinical trial results to show its Lunsumio and Columvi are the best new bispecific therapies in B-cell lymphomas, and is also highlighting patient convenience and economics as it tries to get ahead of AbbVie/Genmab’s rival CD20XCD3-targeting bispecific, Epkinly.
The company is emphasizing the benefits of its approach of using a fixed duration of treatment with Lunsumio (mosunetuzumab) in...